Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.
Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G. Bisso A, et al. Among authors: santarpia l. Cell Cycle. 2013 Jun 1;12(11):1679-87. doi: 10.4161/cc.24757. Epub 2013 May 1. Cell Cycle. 2013. PMID: 23656790 Free PMC article.
Notch is a direct negative regulator of the DNA-damage response.
Vermezovic J, Adamowicz M, Santarpia L, Rustighi A, Forcato M, Lucano C, Massimiliano L, Costanzo V, Bicciato S, Del Sal G, d'Adda di Fagagna F. Vermezovic J, et al. Among authors: santarpia l. Nat Struct Mol Biol. 2015 May;22(5):417-24. doi: 10.1038/nsmb.3013. Epub 2015 Apr 20. Nat Struct Mol Biol. 2015. PMID: 25895060 Free article.
Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast.
Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F, Santarpia L, Aifantis I, Rosato A, Bicciato S, Zambelli A, Del Sal G. Rustighi A, et al. Among authors: santarpia l. EMBO Mol Med. 2014 Jan;6(1):99-119. doi: 10.1002/emmm.201302909. Epub 2013 Dec 15. EMBO Mol Med. 2014. PMID: 24357640 Free PMC article.
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ. Adams BD, et al. Among authors: santarpia l. Cancer Res. 2016 Feb 15;76(4):927-39. doi: 10.1158/0008-5472.CAN-15-2321. Epub 2015 Dec 16. Cancer Res. 2016. PMID: 26676753 Free PMC article.
Targeting triple negative breast cancer: is p53 the answer?
Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A. Turner N, et al. Among authors: santarpia l. Cancer Treat Rev. 2013 Aug;39(5):541-50. doi: 10.1016/j.ctrv.2012.12.001. Epub 2013 Jan 12. Cancer Treat Rev. 2013. PMID: 23321033 Review.
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. De Mattos-Arruda L, et al. Among authors: santarpia l. Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495. Oncotarget. 2015. PMID: 26452030 Free PMC article.
152 results